全文获取类型
收费全文 | 2028篇 |
免费 | 173篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 77篇 |
妇产科学 | 48篇 |
基础医学 | 321篇 |
口腔科学 | 30篇 |
临床医学 | 378篇 |
内科学 | 298篇 |
皮肤病学 | 21篇 |
神经病学 | 150篇 |
特种医学 | 37篇 |
外科学 | 189篇 |
综合类 | 23篇 |
预防医学 | 266篇 |
眼科学 | 24篇 |
药学 | 213篇 |
中国医学 | 3篇 |
肿瘤学 | 125篇 |
出版年
2023年 | 9篇 |
2022年 | 9篇 |
2021年 | 44篇 |
2020年 | 30篇 |
2019年 | 44篇 |
2018年 | 43篇 |
2017年 | 46篇 |
2016年 | 40篇 |
2015年 | 43篇 |
2014年 | 56篇 |
2013年 | 77篇 |
2012年 | 107篇 |
2011年 | 129篇 |
2010年 | 52篇 |
2009年 | 73篇 |
2008年 | 125篇 |
2007年 | 127篇 |
2006年 | 128篇 |
2005年 | 134篇 |
2004年 | 110篇 |
2003年 | 106篇 |
2002年 | 92篇 |
2001年 | 39篇 |
2000年 | 32篇 |
1999年 | 34篇 |
1998年 | 16篇 |
1997年 | 27篇 |
1996年 | 19篇 |
1995年 | 19篇 |
1994年 | 18篇 |
1993年 | 13篇 |
1992年 | 29篇 |
1991年 | 29篇 |
1990年 | 21篇 |
1989年 | 25篇 |
1988年 | 24篇 |
1987年 | 19篇 |
1986年 | 20篇 |
1985年 | 28篇 |
1984年 | 18篇 |
1983年 | 9篇 |
1982年 | 9篇 |
1980年 | 7篇 |
1979年 | 19篇 |
1978年 | 6篇 |
1976年 | 8篇 |
1974年 | 7篇 |
1973年 | 8篇 |
1969年 | 9篇 |
1968年 | 7篇 |
排序方式: 共有2211条查询结果,搜索用时 15 毫秒
71.
Dennis J Johnson CY Adediran AS de Andrade M Heit JA Morange PE Trégouët DA Gagnon F 《Blood》2012,119(10):2392-2400
The endothelial protein C receptor (EPCR) limits thrombus formation by enhancing activation of the protein C anticoagulant pathway, and therefore may play a role in the etiology of thrombotic disorders. The rs867186 single-nucleotide polymorphism in the PROCR gene (g.6936A > G, c.4600A > G), resulting in a serine-to-glycine substitution at codon 219, has been associated with reduced activation of the protein C pathway, although its association with thrombosis risk remains unclear. The present study is a highly comprehensive systematic review and meta-analysis, including unpublished genome-wide association study results, conducted to evaluate the evidence for an association between rs867186 and 2 common thrombotic outcomes, venous thromboembolism (VTE) and myocardial infarction (MI), which are hypothesized to share some etiologic pathways. MEDLINE, EMBASE, and HuGE Navigator were searched through July 2011 to identify relevant epidemiologic studies, and data were summarized using random-effects meta-analysis. Twelve candidate genes and 13 genome-wide association studies were analyzed (11 VTE and 14 MI, including 37,415 cases and 84,406 noncases). Under the additive genetic model, the odds of VTE increased by a factor of 1.22 (95% confidence interval, 1.11-1.33, P < .001) for every additional copy of the G allele. No evidence for association with MI was observed. 相似文献
72.
Bouleti C Iung B Laouénan C Himbert D Brochet E Messika-Zeitoun D Détaint D Garbarz E Cormier B Michel PL Mentré F Vahanian A 《Circulation》2012,125(17):2119-2127
73.
74.
Emilie Morin France Berthelet John Weisnagel Martin Bidlingmaier Omar Serri 《Pituitary》2012,15(1):97-100
It has been suggested that treatment with adequate dose titration of pegvisomant, a GH antagonist, up to a maximum of 40 mg
daily, can achieve IGF-1 normalisation in virtually all patients with acromegaly. On the other hand, temozolomide (TMZ), an
alkylating cytostatic agent, has been reported to reduce pituitary tumour size and hormone hypersecretion in a small number
of aggressive pituitary macroadenomas. In this paper we report the case of a patient resistant to very high doses of pegvisomant
used in combination with somatostatin analogs (SSA) and to TMZ therapy. The patient, initially a 22 year-old man with an invasive
GH-secreting pituitary macroadenoma (IGF-1, 371% upper limit of normal), had active acromegaly despite a repeat transsphenoidal
surgery followed by radiotherapy and SSA (octreotide 800 μg sc daily) (IGF-1, 262% ULN). In combination with SSA, pegvisomant
was started at 20 mg daily and doses were titrated up to 60 mg daily. IGF-1 was moderately reduced and stabilized at 200%
ULN after 1 year of treatment. Serum pegvisomant level was 30,500 ng/l, the denaturalized GHBP concentration 1,120 pM and
the endogenous GH level was 220 μg/l. Pegvisomant was stopped and TMZ therapy was given for 5 cycles. However, the patient
reported an increase of acromegaly symptoms and the serum IGF-1 was raised to the same level prior to pegvisomant therapy.
Consequently, pegvisomant was tried again with doses up to 100 mg daily finally resulting in normalisation of serum IGF-1
level and improvement of acromegaly symptoms and patient well-being. We conclude that in some patients with severe acromegaly
refractory to multimodal therapy, biochemical control may be difficult to attain with conventional doses of pegvisomant or
TMZ therapy. 相似文献
75.
76.
Dominique Bertrand Geoffroy Desbuissons Nicolas Pallet Alain Debure Albane Sartorius Dany Anglicheau Marie‐France Mamzer Christophe Legendre Rebecca Sberro‐Soussan 《Transplant international》2013,26(2):e4-e7
The side‐effects associated with the immunosuppressive drug sirolimus are numerous and constitute a major limitation for its use in renal transplantation. In this study, we describe two cases of renal transplant recipients treated with sirolimus who developed pericardial tamponade associated with interstitial pneumonia, proteinuria, microcytic anemia and, in one case, lymphocytic meningitidis. An extensive search for infectious agents was negative, and all symptoms disappeared after sirolimus interruption. Therefore, this case demonstrates for the first time that sirolimus can cause pericardial tamponade as well as lymphocytic meningitidis. 相似文献
77.
Abdallah Fayssoil Lee S. Nguyen Tanya Stojkovic Helene Prigent Robert Carlier Helge Amthor Jean Bergounioux Justine Zini Sebastien Damez-Fontaine Karim Wahbi Pascal Laforet Guillaume Nicolas Anthony Behin Guillaume Bassez France Leturcq Rabah Ben Yaou Nicolas Mansencal Djillali Annane Frdric Lofaso David Orlikowski 《Muscle & nerve》2022,65(1):89-95
78.
79.
80.
Acute systemic inflammation induces central mitochondrial damage and mnesic deficit in adult Swiss mice 总被引:1,自引:0,他引:1
Noble F Rubira E Boulanouar M Palmier B Plotkine M Warnet JM Marchand-Leroux C Massicot F 《Neuroscience letters》2007,424(2):106-110
The aim of this study was to investigate how the brain is affected during systemic inflammation. For this purpose, Swiss mice were challenged with a single intraperitoneal dose of lipopolysaccharide (LPS; 250microg/mouse) to mimic aspects of systemic infection. Spatial learning in Y-maze test demonstrated a differential learning profile during the training test between control and LPS-treated mice, with an alteration in the latter group. We show that systemic LPS-induced inflammation and oxidative injury as assessed by reactive oxygen species (ROS) and nitrites/nitrates (NOx) production associated with reduced glutathione (GSH) depletion, cyclooxygenase-2 (COX-2) expression, and lipid peroxidation. LPS also induced a loss in mitochondrial integrity as shown by a significant decrease in membrane potential and impairment in mitochondrial redox activity. Thus, peripheral inflammation by producing brain inflammation and oxidative injury causes mnesic deficits. It remains to determine whether such events can induce neuronal dysfunction/degeneration and, with time, lead to cholinergic deficiency, amyloid deposits and cognitive impairments as they occur in Alzheimer's disease. 相似文献